Business
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces first quarter 2026 financial results and provides a corporate update.
About this update from Intensity Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Cash and cash equivalents of $10.2 million as of March 31, 2026","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":63,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)","length":251,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":251,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":122,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":137,"olType":false},{"type":"text","content":"SHELTON, Conn., May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces first quarter 2026 financial results and provides a corporate update.","length":490,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3SolqFRnockqsDCq6mJwFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3OA--/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html","hrefExternal":tru...